GILD · News · 20261030N
Medicare Biktarvy Price Regulation
GILEAD SCIENCES, INC. · 2026-10-30 · Importance 66 · Surprise 48 · In source text
Gilead expects Medicare pricing changes to create an approximately $1.5 billion revenue headwind in 2028 for Biktarvy, its key HIV drug. The company expects Biktarvy sales to decline in 2028 as a result. Management nevertheless forecasts overall HIV revenue growth as newer treatments gain traction.
Key facts
- Gilead warned of a potential $1.5 billion revenue headwind in 2028 due to Medicare pricing changes affecting Biktarvy. source
- Gilead expects Biktarvy sales to decline in 2028, while forecasting overall HIV revenue growth as newer treatments gain traction. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | contingent | -1.4% | Gilead warned of a potential $1.5 billion revenue headwind in 2028 due to Medicare pricing changes affecting Biktarvy. |